AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17176529 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 15363481 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 15363481 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 11020746 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 50
Study 11020746 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 50
Study 8829417 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 70 mg in 7.5% glucose
Number of subjects: 20
Study 8829417 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 60 mg in saline
Number of subjects: 20
Study 1640755 — intervention group
Group type: EXPERIMENTAL
Intervention: Random CO2 inhalation
Number of subjects: 5
Study 1640755 — intervention group
Group type: EXPERIMENTAL
Intervention: Random work rate forcing
Number of subjects: 5
Study 1640755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous CO2 inhalation and exercise
Number of subjects: 5
Study 6340511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MCA injection
Number of subjects: 23
Study 6340511 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MCA injection after uterine lavage
Number of subjects: 23
Study 6340511 — intervention group
Group type: EXPERIMENTAL
Intervention: Two MCA injections 1 month apart
Number of subjects: 23
Study 6340511 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiopaque MCA
Number of subjects: 23
Study 30132724 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Education Program (YEP)
Number of subjects: 792
Study 31488785 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious content of delusions and hallucinations
Number of subjects: 100
Study 31488785 — intervention group
Group type: EXPERIMENTAL
Intervention: Diversity of religious and spiritual themes
Number of subjects: 100
Study 31488785 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of contact with God and other religious figures
Number of subjects: 100
Study 31488785 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of 'visions'
Number of subjects: 100
Study 31488785 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious content
Number of subjects: 100
Study 26873658 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care and silicone foam border dressing
Number of subjects: 80
Study 26873658 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 26091383 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial, modified-release (MR) Doxycycline 40 mg
Number of subjects: 662
Study 26091383 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg
Number of subjects: 662
Study 26091383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 23559535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (70.6% of patients attended)
Number of subjects: 3560
Study 21815708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10-20 mg/day)
Number of subjects: 7832
Study 19531281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 10, 30 or 60 ml for 12 weeks
Number of subjects: 207
Study 19531281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 60 ml
Number of subjects: 207
Study 19531281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 16835825 — intervention group
Group type: EXPERIMENTAL
Intervention: U/DD (stepping up for 1 second and stepping down for 2 seconds)
Number of subjects: 20
Study 16835825 — intervention group
Group type: COMPARATOR
Intervention: U/D (stepping up and down in the same rhythm of one second each)
Number of subjects: 20
Study 15390050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25-4.0 mg/day)
Number of subjects: 267
Study 15390050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 11436681 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alopecia areata (AA)
Number of subjects: 18
Study 11436681 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 18
Study 9492089 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical JNCL (homozygous for the common 1.02 kb deletion)
Number of subjects: 191
Study 9492089 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical JNCL (heterozygous for the common 1.02 kb deletion)
Number of subjects: 191
Study 9492089 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical JNCL (heterozygous for the common 1.02 kb deletion)
Number of subjects: 191
Study 9492089 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical JNCL (no common 1.02 kb deletion)
Number of subjects: 191
Study 9492089 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical JNCL (deficient PPT levels)
Number of subjects: 191
Study 8058422 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ; 5 mg/kg/dose Q6h for 36 hr)
Number of subjects: 14
Study 8058422 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (AMINO; 8 mg/kg bolus then 2.5 mg/kg Q12h for 36 hr)
Number of subjects: 14
Study 8058422 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ)
Number of subjects: 14
Study 8058422 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (AMINO)
Number of subjects: 14
Study 2680474 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 12
Study 2680474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise (DE)
Number of subjects: 12
Study 31661578 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS
Number of subjects: 75
Study 31661578 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS
Number of subjects: 75
Study 31661578 — intervention group
Group type: COMPARATOR
Intervention: Transient Placebo TENS
Number of subjects: 75
Study 31002710 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-based PM tasks
Number of subjects: 0
Study 31002710 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based PM tasks
Number of subjects: 0
Study 31002710 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward condition
Number of subjects: 0
Study 31002710 — intervention group
Group type: COMPARATOR
Intervention: No-reward condition
Number of subjects: 0
Study 27999118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OCs)
Number of subjects: 1508
Study 27999118 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin
Number of subjects: 1508
Study 27999118 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous menses
Number of subjects: 1508
Study 27999118 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-induced menses
Number of subjects: 1508
Study 27999118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (OCs) induced menses
Number of subjects: 1508
Study 26711755 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day
Number of subjects: 0
Study 26711755 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 8 mg/kg/day
Number of subjects: 0
Study 26711755 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 10 mg/kg/day
Number of subjects: 0
Study 26711755 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg/day to 10 mg/kg/day
Number of subjects: 0
Study 24004650 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Short Wave Diathermy (CSWD)
Number of subjects: 24
Study 24004650 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Short Wave Diathermy (PSWD)
Number of subjects: 24
Study 22164808 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-assisted activities (therapeutic riding treatment)
Number of subjects: 24
Study 19386439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 19
Study 16710114 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol
Number of subjects: 8
Study 16710114 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.5 mg D9‐tétrahydrocannabinol (THC)
Number of subjects: 8
Study 16710114 — intervention group
Group type: EXPERIMENTAL
Intervention: 45.7 mg THC as a cannabis milk decoction
Number of subjects: 8
Study 16710114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16710114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis Influence Factor (CIF)
Number of subjects: 8
Study 16710114 — intervention group
Group type: EXPERIMENTAL
Intervention: THC, 11‐OH‐THC and THC‐COOH blood concentrations
Number of subjects: 8
Study 16710114 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulator tests
Number of subjects: 8
Study 12705062 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg daily)
Number of subjects: 0
Study 12705062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg daily)
Number of subjects: 0
Study 12705062 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg daily)
Number of subjects: 0
Study 12705062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2 selective NSAIDs (general)
Number of subjects: 0
Study 12705062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-protective agents (proton pump inhibitors or misoprostol)
Number of subjects: 0
Study 12705062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0
Study 10888949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar discography
Number of subjects: 26
Study 10888949 — intervention group
Group type: COMPARATOR
Intervention: Control groups (patients with somatization disorder without discography and patients with low back pain observed for 1 year after discography without surgery)
Number of subjects: 26
Study 9082601 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10-30 mg 4 times a day)
Number of subjects: 12
Study 9082601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1431010 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily, increased to 30 mg after 1 week)
Number of subjects: 101
Study 1431010 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50 mg daily, increased to 100 mg after 1 week)
Number of subjects: 101
Study 1431010 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 101
Study 1431010 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 101
Study 1431010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 101
Study 3904312 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bromocriptine per os
Number of subjects: 20
Study 3904312 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 20
Study 31395229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-umbilical vein injection of carbetocin (1 mL containing 100 μg carbetocin diluted in 20 mL normal saline 0.9%)
Number of subjects: 200
Study 31395229 — intervention group
Group type: COMPARATOR
Intervention: Intra-umbilical vein injection of oxytocin (20 IU diluted in 20 mL normal saline 0.9%)
Number of subjects: 200
Study 28895655 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (titrated doses targeting fasting normoglycaemia)
Number of subjects: 0
Study 27101881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (schools with trained teachers)
Number of subjects: 464
Study 27101881 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools without trained teachers)
Number of subjects: 464
Study 24910271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep bolus injection into the mid‐ to lateral cheek
Number of subjects: 0
Study 24910271 — intervention group
Group type: EXPERIMENTAL
Intervention: Local mid‐ to deep dermal injection into the nasolabial fold
Number of subjects: 0
Study 24910271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both deep injection into the mid‐ to lateral cheek and local mid‐ to deep dermal injection into the nasolabial fold
Number of subjects: 0
Study 22399125 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine combined with low dose fentanyl (Group B)
Number of subjects: 60
Study 22399125 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine combined with low dose fentanyl (Group L)
Number of subjects: 60
Study 20070556 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback (IFB) of HbA1c results via point‐of‐care fingerstick testing
Number of subjects: 215
Study 20070556 — intervention group
Group type: COMPARATOR
Intervention: Conventional feedback of HbA1c results via venipuncture and laboratory assessment
Number of subjects: 215
Study 20070556 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback (IFB) of HbA1c results
Number of subjects: 215
Study 20070556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingersticks (IFB)
Number of subjects: 215
Study 18184902 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet (0.8 g protein/kg body weight; 35% animal proteins, 35% textured soy protein, 30% vegetable proteins)
Number of subjects: 41
Study 16884968 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg/day
Number of subjects: 0
Study 16884968 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg/day
Number of subjects: 0
Study 16884968 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study 12478070 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai-CDC regimen
Number of subjects: 139
Study 12478070 — intervention group
Group type: COMPARATOR
Intervention: HIVNET-012 regimen
Number of subjects: 139
Study 10447133 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education according to WHO's recommendations on breastfeeding
Number of subjects: 1250
Study 7586939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lys(B28), Pro(B29)-human insulin (lispro)
Number of subjects: 0
Study 7586939 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 0
Study 2179176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g suspension, 4 times a day orally)
Number of subjects: 45
Study 2179176 — intervention group
Group type: COMPARATOR
Intervention: Standard oral hygiene (control group)
Number of subjects: 45
Study 222741 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 10
Study 28766084 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 598
Study 28766084 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 598
Study 28766084 — intervention group
Group type: COMPARATOR
Intervention: Standard usual care
Number of subjects: 598
Study 25495505 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive group
Number of subjects: 25
Study 25495505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 25495505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 23984182 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT treatment
Number of subjects: 96
Study 21458532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT), 40 sessions
Number of subjects: 87
Study 21458532 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 87
Study 18059423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning intervention
Number of subjects: 47
Study 18059423 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 47
Study 18059423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning and education interventions
Number of subjects: 47
Study 16099416 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition Heuristic (RH) with additional cue information for recognized cities
Number of subjects: 0
Study 16099416 — intervention group
Group type: COMPARATOR
Intervention: Recognition Heuristic (RH) without additional cues
Number of subjects: 0
Study 12571183 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH for ovulation induction
Number of subjects: 41
Study 11458246 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 positive women
Number of subjects: 638
Study 11458246 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 negative women
Number of subjects: 638
Study 11458246 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 638
Study 9433422 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐ANP concentration
Number of subjects: 1252
Study 9433422 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP concentration
Number of subjects: 1252
Study 9433422 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP concentration of 17.9 pg/mL or more
Number of subjects: 1252
Study 8017305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 43
Study 8017305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization with heparin
Number of subjects: 43
Study 8017305 — intervention group
Group type: COMPARATOR
Intervention: Peripheral angiography without heparin
Number of subjects: 43
Study 2598979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon with surfactants (9-lauryl ether as spray, sodium glycocholate as spray or powder)
Number of subjects: 0
Study 2598979 — intervention group
Group type: EXPERIMENTAL
Intervention: Human calcitonin with surfactants (dihydrofusinate as spray or powder, glycocholate as spray)
Number of subjects: 0
Study 2598979 — intervention group
Group type: EXPERIMENTAL
Intervention: Powders and spray solutions of glucagon and calcitonin
Number of subjects: 0
Study 4885026 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 11
Study 7013055 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac 100 mg b.i.d. (plus indomethacin placebo)
Number of subjects: 42
Study 7013055 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 25 mg t.i.d. (plus sulindac placebo)
Number of subjects: 42
Study 31006118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 42
Study 29105247 — intervention group
Group type: EXPERIMENTAL
Intervention: Musicians
Number of subjects: 0
Study 29105247 — intervention group
Group type: COMPARATOR
Intervention: Nonmusicians
Number of subjects: 0
Study 26871805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ketamine 0.5 mg/kg (group K)
Number of subjects: 104
Study 26871805 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group S)
Number of subjects: 104
Study 25603666 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 158
Study 25603666 — intervention group
Group type: COMPARATOR
Intervention: Delayed primary closure
Number of subjects: 158
Study 22428119 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve subjects (test group) allowed to gaze freely during various tasks (photographic images, video, computer tasks, walking)
Number of subjects: 20
Study 22428119 — intervention group
Group type: COMPARATOR
Intervention: Control subjects instructed to gaze at bright features and dark features in phase 1
Number of subjects: 20
Study 20204984 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus psychological preparation
Number of subjects: 85
Study 20204984 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 85
Study 17586452 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 63
Study 17586452 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate (20mgSb(5)/kg body weight daily for 14 days)
Number of subjects: 63
Study 15637501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (various forms, dosage not specified)
Number of subjects: 4
Study 12000468 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 21
Study 12000468 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 21
Study 9790462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation plus Nd‐YAG laser therapy
Number of subjects: 15
Study 9790462 — intervention group
Group type: COMPARATOR
Intervention: Dilatation alone
Number of subjects: 15
Study 9363233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal capsules containing seminal plasma
Number of subjects: 87
Study 9363233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lubrication jelly)
Number of subjects: 87
Study 2533449 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg twice weekly
Number of subjects: 35
Study 2533449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 333643 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate (Plaquenil)
Number of subjects: 134
Study 333643 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 134
Study 333643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 30955461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol or dexmedetomidine for sedation
Number of subjects: 0
Study 30955461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic prevention of delirium
Number of subjects: 0
Study 30955461 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of delirium
Number of subjects: 0
Study 30955461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic strategies to improve sleep
Number of subjects: 0
Study 28388136 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase modulated saturation pulse
Number of subjects: 0
Study 28388136 — intervention group
Group type: COMPARATOR
Intervention: Other dipolar recoupling sequences
Number of subjects: 0
Study 26040620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 63
Study 26040620 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 63
Study 23379498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse high-volume hemofiltration (PHVHF)
Number of subjects: 30
Study 23379498 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 30
Study 21325466 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone/ethinyl estradiol (3 mg/30 μg)
Number of subjects: 46
Study 21325466 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg)
Number of subjects: 46